Build Your Own Case Study: A Glimpse at Optimal T2D Management: Enhancing Outcomes with GLP-1 RAs

Estimated Time
1.00 hour

Release Date
Oct 28, 2022

Expiration Date
Oct 27, 2023

Think you fully understand the differences between available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their use in the management of Type 2 diabetes (T2D) and comorbidities? Clinicians may under-use GLP-1 RAs or not fully understand the differences between all the available GLP-1 RAs. As a result, unmet needs in T2D management persist, particularly in some ethnic and socioeconomic populations.

Test your knowledge about newest guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2D using GLP-1 RAs by building your own case studies. This will help your patients achieve A1C targets, particularly those with comorbidities including obesity, cardiovascular disease, NAFLD/NASH, transplants, PCOS and more!  Additionally, this will help you identify various social determinants of health (SDoH) that may be unrecognizable and help you direct your patients in changing important modifiable behaviors (like sleep, stress, smoking cessation, and alcohol use).

At any point in this Build Your Own Case Study, expert endocrinologists will shed light on current recommendations and evidence for GLP-1 RAs in the management of T2D along with obesity, cardiovascular diseases, and other comorbidities. Our expert faculty will also offer insights on individualizing treatment plans to help your patients reach their goals and reduce comorbidity risks.

Think you have all the tools you need to help your patients? If so, post-test and claiming credit will be a breeze! 


Accreditation and Disclosure Information

This CE activity is intended for physicians, fellows, NPs, PAs, nurses, and pharmacists who provide care for individuals with T2D.

After completing this CE activity, the participant should be better able to:

  • Assess the consequences of suboptimal management of T2D
  • Adopt guideline recommended treatment approaches including the appropriate us of GLP-1 RAs
  • Evaluate available GLP-1 RAs with respect to mechanism of action, dosing and administration, glycemic and extra-glycemic effects, and adverse events (AEs)
  • Optimize the use of GLP-1 RAs to improve patient care and outcomes


Part 1: Unmet needs in T2D and how GLP-1 RAs might address them (expert commentary)

  • Challenges in attaining and maintaining A1c goals
  • Managing comorbidities (eg, obesity, cardiovascular [CV] risk, chronic kidney disease)
  • Guideline discordance; under-utilization of GLP-1 RAs
  • GLP-1 RA mechanism of action; the role of GLP in the pathophysiology of T2D; pleiotropic effects on comorbidities (eg, hyperlipidemia, hypertension, and fatty liver) and syndromes (eg, osteoporosis, sleep apnea) that commonly co-occur with diabetes

Part 2: Build your own case (learner interaction interspersed with expert commentary regarding choices)

  • Case part 1: Initiating therapy (including shared decision making for treatment selection; use of GLP-1 RAs in patients with a neuroendocrine tumor or pancreatitis) 
  • Case part 2: Dosing, dosage adjustment, and mode of administration (subcutaneous vs oral; daily vs weekly administration)
  • Case part 3: Glycemic and extra-glycemic effects (eg, A1c reduction, weight loss, CV risk reduction)
  • Case part 4: Safety concerns; monitoring for and mitigating AEs (eg, gastrointestinal [GI] effects, thyroid C-cell tumors, pancreatitis, diabetic retinopathy, acute kidney injury, chronic kidney disease, heart failure, hypersensitivity reactions, acute gallbladder disease)

Part 3: The role of GLP-1 RAs (expert commentary)

  • Place in treatment (eg, for patients who need to minimize hypoglycemia or minimize weight gain/promote weight loss, or are at high risk for or have atherosclerotic CV disease, or for whom metformin is contraindicated); role of GLP-1 RAs vs dipeptidyl peptidase-4 [DPP-4] inhibitors 
  • Guideline concordance

The activity concludes with a recap of key points and an evaluation; it includes downloadable resources, eg, practice aids, patient education materials; all approved GLP-1 RAs (ie, dulagluatide, exenatide, liraglutide, lixisenatide, and semaglutide) will be included


ACCME with Commendation LogoThe Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medical Learning Institute, Inc. (MLI). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 


AMA PRA Category 1 CreditsTM
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this activity is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


JA Logo

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and Endocrine Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



AAPA Credit Designation Statement
AAPA LogoMedical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 27, 2023. PAs should only claim credit commensurate with the extent of their participation.


Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development actiity will be awarded 1.0 contact hour and 0.75 contact hour in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Educaton.

Universal Acticity Number: JA0007322-0000-22-099-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement 
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.



This activity is supported by an educational grant from Novo Nordisk.

Medical Learning Institute, Inc., and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity. 

Sean Wharton, MD, FRCPC, PharmD, Medical Director, The Wharton Medical Clinic – Diabetes and Weight Management Centre, Ontario, Canada

Sean Wharton MD, PharmD, FRCPC has a financial interest/relationship or affiliation in the form of: Advisory Board/Consultant for Bausch Health Canada, Eli Lilly, and Novo Nordisk; Research Grant Support for Bausch Health Canada and Novo Nordisk.

Carly E. Kelley, MD, MPH, ENCU, Assistant Professor of Medicine, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC

Carly E. Kelly, MD, MPH, ECNU has no relevant financial relationships with ineligible companies to disclose for this educational activity.  

Donna Ryan, MD, Professor Emerita, Pennington Biomedical Research Center, Baton Rouge, LA

Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand; Speakers’ Bureau with Novo Nordisk; Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm; Co-chair of steering committee for the SELECT Trial for Novo Nordisk.

Jabiz Behzadpour, DO, Endocrinology Physician, Riverside Healthcare, Kankakee, IL

Jabiz Behzadpour, DO has no relevant financial relationships with ineligible companies to disclose for this educational activity.  

All of the relevant financial relationships of individuals for this activity have been mitigated.

The planners and content/peer reviewers from Medical Learning Institute, Inc. and the Endocrine Society do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.  Once submitted, the certificate will be automatically generated as a PDF online.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Marissa Grossman via email at

The Endocrine Society and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and the Endocrine Society.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc., Endocrine Society, or any of its partners, providers, and/or supporters.


MLI and ES Logos